These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 9210005)
1. Cefepime versus ceftazidime in the treatment of lower respiratory tract infections. Aufiero A; Sturani C; Zanon P; Marruchella A; Michetti G; Nicolin E; Sella D; Goglio A; Silleni M; La Regina A J Chemother; 1997 Jun; 9(3):213-8. PubMed ID: 9210005 [TBL] [Abstract][Full Text] [Related]
2. A comparative study of cefepime and ceftazidime in the treatment of community-acquired lower respiratory tract infections. Léophonte P; Bertrand A; Nouvet G; Muir JF; Lucht F; Delaval P; Depierre A; Hughes F; Ulmer M; Grès JJ J Antimicrob Chemother; 1993 Nov; 32 Suppl B():165-73. PubMed ID: 8150760 [TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of cefepime versus ceftazidime in the treatment of severe infections. Huang CK; Chen YS; Lee SS; Lin WR; Tsai HC; Lin HH; Wann SR; Chen JY; Yen MY; Liu YC J Microbiol Immunol Infect; 2002 Sep; 35(3):159-67. PubMed ID: 12380788 [TBL] [Abstract][Full Text] [Related]
4. International comparative study of cefepime and ceftazidime in the treatment of serious bacterial infections. Hoepelman AI; Kieft H; Aoun M; Kosmidis J; Strand T; Verhoef J; Gillespie SH; Riddell J; Varghese G; Meunier F J Antimicrob Chemother; 1993 Nov; 32 Suppl B():175-86. PubMed ID: 8150761 [TBL] [Abstract][Full Text] [Related]
5. Cefepime versus ceftazidime for the treatment of serious bacterial infections. Ponce-de-León A; López-Meneses M; Sifuentes-Osornio J Diagn Microbiol Infect Dis; 1999 Dec; 35(4):263-8. PubMed ID: 10668583 [TBL] [Abstract][Full Text] [Related]
6. A new therapeutic option for the treatment of pneumonia. McCabe R; Chirurgi V; Farkas SA; Haddow A; Heinz G; Greene S Am J Med; 1996 Jun; 100(6A):60S-67S. PubMed ID: 8678099 [TBL] [Abstract][Full Text] [Related]
7. A randomized trial of cefepime and ceftazidime for the treatment of community-acquired pneumonia. Bonfitto P; Lamorgese V; De Vietro T; Malerba M; Rizzello L; Scoditti S; Zuin R J Chemother; 1999 Aug; 11(4):273-7. PubMed ID: 10465129 [TBL] [Abstract][Full Text] [Related]
9. Empiric use of cefepime in the treatment of lower respiratory tract infections in children. Bradley JS; Arrieta A Pediatr Infect Dis J; 2001 Mar; 20(3):343-9. PubMed ID: 11303848 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of cefepime in late-onset ventilator-associated pneumonia in infants: a pilot randomized and controlled study. Shahid SK Ann Trop Med Parasitol; 2008 Jan; 102(1):63-71. PubMed ID: 18186979 [TBL] [Abstract][Full Text] [Related]
11. A randomized trial of cefepime (BMY-28142) and ceftazidime for the treatment of pneumonia. Edelstein H; Chirurgi V; Oster S; Karp R; Cassano K; Aiken S; McCabe R J Antimicrob Chemother; 1991 Oct; 28(4):569-75. PubMed ID: 1761451 [TBL] [Abstract][Full Text] [Related]
12. A comparative study of cefepime versus ceftazidime as empiric therapy of febrile episodes in neutropenic patients. Wang FD; Liu CY; Hsu HC; Gau JP; Chau WK; Haung ML; Ho CH Chemotherapy; 1999; 45(5):370-9. PubMed ID: 10473925 [TBL] [Abstract][Full Text] [Related]
13. Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: a randomized study. Meropenem Lower Respiratory Infection Group. Sieger B; Berman SJ; Geckler RW; Farkas SA Crit Care Med; 1997 Oct; 25(10):1663-70. PubMed ID: 9377880 [TBL] [Abstract][Full Text] [Related]
14. Randomized comparison of cefepime and ceftazidime for treatment of skin, surgical wound, and complicated urinary tract infections in hospitalized subjects. Gentry LO; Rodriguez-Gomez G Antimicrob Agents Chemother; 1991 Nov; 35(11):2371-4. PubMed ID: 1804010 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of cefepime versus ceftazidime in the treatment of adult pneumonia. Lin JC; Yeh KM; Peng MY; Chang FY J Microbiol Immunol Infect; 2001 Jun; 34(2):131-7. PubMed ID: 11456359 [TBL] [Abstract][Full Text] [Related]
16. Randomized comparison of cefepime and ceftazidime for treatment of hospitalized patients with gram-negative bacteremia. Schrank JH; Kelly JW; McAllister CK Clin Infect Dis; 1995 Jan; 20(1):56-8. PubMed ID: 7727671 [TBL] [Abstract][Full Text] [Related]
17. Current and future management of serious skin and skin-structure infections. Schwartz R; Das-Young LR; Ramirez-Ronda C; Frank E Am J Med; 1996 Jun; 100(6A):90S-95S. PubMed ID: 8678103 [TBL] [Abstract][Full Text] [Related]
18. Treatment of urinary tract infections: selecting an appropriate broad-spectrum antibiotic for nosocomial infections. Sharifi R; Geckler R; Childs S Am J Med; 1996 Jun; 100(6A):76S-82S. PubMed ID: 8678101 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. McKinnon PS; Paladino JA; Schentag JJ Int J Antimicrob Agents; 2008 Apr; 31(4):345-51. PubMed ID: 18313273 [TBL] [Abstract][Full Text] [Related]
20. Cefepime versus ceftazidime as empiric therapy for fever in neutropenic patients with cancer. Chandrasekar PH; Arnow PM Ann Pharmacother; 2000 Sep; 34(9):989-95. PubMed ID: 10981242 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]